The supply of plastic bioreactor systems used in manufacturing a wide range of vaccines, monoclonal antibodies and cell and gene therapies has tightened so much during the COVID-19 pandemic that some manufacturers are considering desperate measures to maintain production.
Normally, manufacturers go through enough of these systems, which are designed to be used once and discarded, to produce 5 billion doses of vaccines per year, industry experts say
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?